Skip to content
Home page - Centenary Institute Centenary Institute

Primary menu

  • Research
        • Research

          The latest medical research into our most complex health challenges across cancer, cardiovascular disease and inflammation

          Learn more

        • Cancer
        • Inflammation
        • Cardiovascular
        • Programs
        • Laboratories
        • Diseases
        • Expertises
        • Services and instrumentation
  • Support us
        • Support us

          By supporting the Centenary Institute you can help improve human health through excellence in medical research

          Learn more

        • Workplace giving
        • Host or join a fundraiser
        • Gift in your Will
        • Donate in Memory
  • Impact
        • Impact

          Our research develops new diagnostics, treatments and cures for some of the most deadly and debilitating diseases affecting society today

          Learn more

        • Breakthroughs
        • Community and research
        • Real stories
  • Health hub
        • Health hub

          A range of practical information to assist in the possible preventions to disease through evidence-based research on how the body works.

          Learn more

        • Inflammation
        • The Good Gut Anti-Inflammatory Diet
        • Ageing
        • Exercise Snack Program
  • News & events
        • News & Events

          Explore the latest research breakthroughs and ways you can take part in our series of digital and in-person events

        • News
        • Events
        • Media Hub
  • About us
        • About us

          We are world-leading independent medical research institute that drives collaboration to accelerate and translate solutions to our most complex health challenges

          Learn more

        • Governance
        • Corporate information
        • Annual reports
        • Our researchers
        • Careers and studies
        • Contact
  • Donate
    Centenary Institute > Research > Tuberculosis

Tuberculosis

Tuberculosis (TB) is caused by a bacteria infection and is the world’s top infectious killer.

The bacteria (Mycobacterium tuberculosis) which is spread through the air when people with lung TB cough, sneeze or spit. A person needs to inhale only a few germs to become infected.

Every year, 10 million people fall ill with the disease. Despite being a preventable and curable disease, each year 1.4 million people die from TB. It is also a major contributor to antimicrobial resistance.

Most of the people who fall ill with TB live in low- and middle-income countries however TB is present all over the world. About half of all people with the disease can be found in 8 countries: Bangladesh, China, India, Indonesia, Nigeria, Pakistan, Philippines and South Africa.

At Centenary our research is through a range of measures. Through developing new vaccines and drugs, improving our understanding of TB immunology, discovering new biomarkers and contributing to public policy and practice. As a part of the Centre of Research Excellence in Tuberculosis Control we have the platform to translate new discoveries into more effective tools to control TB.

We have developed a fully synthetic TB vaccine in a proof-of-principle study for a new type of vaccine. The same methods could be used to develop vaccines against other lung infections such as SARS-CoV-2.

We have also developed a new protein fusion vaccine called CysVac2 that is very effective against TB infection when given as an intramuscular injection. Delivery of this multistage vaccine promotes the development of lung-resident memory T cells that we have previously shown can protect against TB. This is a promising candidate vaccine for clinical development.

We have identified a signature based on gene expression in blood cells that distinguishes early tuberculosis disease from people with latent TB Infection and those with no evidence of TB infection. This blood biomarker can be used to help detect TB patients at an early stage.

In collaboration we have shown that synthetic analogues of naturally occurring products that have a common protein target in mycobacteria can kill the TB bacillus growing in humans.

Professor Warwick Britton AO, Head of Tuberculosis Research Program leads this research

Icons with Text on Sidebar

  • It is the leading cause of death of people with HIV

  • About one-quarter of the world’s population is estimated to be infected by TB bacteria

  • Only 5-15% of all infected people will fall ill with active TB disease

  • In 2019, 44% of new cases of TB occurred in South-East Asian region and 18% in the Western Pacific region.

Themes

  • Inflammation

    Inflammation

Research Field Type

  • Diseases

All Research fields

  • Alzheimer's disease

  • AML – Acute Myeloid Leukaemia

  • Asthma

  • Bioinformatics

  • COPD – Chronic obstructive pulmonary disease

  • COVID-19

  • Diabetes

  • Epigenetics

  • Genetic heart disease

  • GvHD – Graft vs Host Disease

  • Liver disease

  • Lung Cancer

  • Melanoma

We have developed a fully synthetic TB vaccine in a proof-of-principle study for a new type of vaccine. The same methods could be used to develop vaccines against other lung infections such as SARS-CoV-2.

We have also developed a new protein fusion vaccine called CysVac2 that is very effective against TB infection when given as an intramuscular injection. Delivery of this multistage vaccine promotes the development of lung-resident memory T cells that we have previously shown can protect against TB. This is a promising candidate vaccine for clinical development.

We have identified a signature based on gene expression in blood cells that distinguishes early tuberculosis disease from people with latent TB Infection and those with no evidence of TB infection. This blood biomarker can be used to help detect TB patients at an early stage.

In collaboration we have shown that synthetic analogues of naturally occurring products that have a common protein target in mycobacteria can kill the TB bacillus growing in humans.

Professor Warwick Britton AO, Head of Tuberculosis Research Program leads this research

Subscribe to receive news on
research updates and free events

Newsletter

The Centenary Institute is a world-leading independent Medical Research Institute.

We acknowledge the Gadigal of the Eora Nation, the traditional custodians of the Country on which the Centenary Institute stands.

About

  • About
  • Governance
  • Corporate information

Research

  • Programs
  • Our researchers
  • News
  • Media hub

Careers & studies

  • Career opportunities
  • Life at Centenary

Links

  • Contact
  • Privacy statement

Contact us

Building 93, Royal Prince Alfred Hospital
Missenden Rd
Camperdown NSW 2050 Australia
Telephone +61 2 9565 6100
Fax +61 2 9565 6101

Centenary Institute ABN 22 654 201 090 (DGR 1) • Centenary Institute Medical Research Foundation ABN 85 778 244 012 (DGR 2)
© 2017 Centenary Institute of Cancer Medicine and Cell Biology.

  • Linkedin
  • Facebook
  • Twitter
  • Youtube
  • Instagram